My Father, My Brother, and Me

Press Reaction

My Father, My Brother, and Me

CORRESPONDENT
Dave Iverson

PRODUCED AND DIRECTED BY
Dave Iverson and Michael Schwarz

EXERCISE INSTRUCTOR: Reach all the way down to the floor without moving your feet--

ANNOUNCER: Living with Parkinson's disease, a story FRONTLINE correspondent Dave Iverson and his family know firsthand.

ADELAIDE: I hadn't thought it would happen. But it has happened.

NARRATOR: Parkinson's affects a million Americans

TOM SHEARER: I have a mindset that I am going to-not going to let this blankety Parkinson's get me down.

NARRATOR: And it's been front and center in the debate over embryonic stem cell science.

Pres. GEORGE W. BUSH: This bill would support the taking of innocent human life, so I vetoed.

MICHAEL J. FOX, Actor: You know, when you're talking about the potential to heal and cure so many, and it not going forward, it pissed me off and I wanted to do something.

NARRATOR: Now the politics have changed, but the quest for a cure continues.

MATTHEW FARRER, Ph.D., Mayo Clinic, Jacksonville: How close are we? We're a lot closer than we were 10 years ago, a lot closer.

NARRATOR: Tonight on FRONTLINE, correspondent Dave Iverson tracks the pursuit of Parkinson's and his own family journey.

DAVE IVERSON, FRONTLINE: [voice-over] It isn't dramatic. It's a disease of inches. A hand starts to shake, a step becomes a shuffle, life in gradual slow motion. Parkinson's arrives without fanfare. You're jogging at the gym one day, and you notice that one arm isn't swinging the same as the other. In time, other signs accumulate. A leg starts to tingle. A finger trembles. None of it seems like a big deal, so you keep living your life.

For me, that meant continuing to host radio and TV shows in San Francisco and doing my best to ignore what wouldn't go away. It took two years before that odd collection of symptoms formed a whole diagnosis. I had Parkinson's, and it was about to send my life in a new direction.

It's not the worst diagnosis. Right now, I'm doing fine.

EXERCISE INSTRUCTOR: Cross your fingers. Thumbs up. Press!

DAVE IVERSON: But as everyone in this Parkinson's exercise class told me, the disease is a relentless foe, handing out its challenges one by one.

CLASS MEMBER: There's something about the inevitability of it. It's a very gradual disease, but inevitably, it's going to get you.

CLASS MEMBER: And you go through a period of adjusting, when you realize that your life is going to be different than you had imagined.

DAVE IVERSON: Life changes for Parkinson's patients when a key neurotransmitter called dopamine goes missing. Dopamine is like the oil that lubricates your motor system. Without it, muscles stiffen, arms shake, sometimes you stutter and stop.

EXERCISE INSTRUCTOR: By counting your steps, you break up that festination problem.

DAVE IVERSON: Drugs help for a while, and a new surgical technique called deep brain stimulation can relieve symptoms for several years.

EXERCISE INSTRUCTOR: And go, and go, and go--

DAVE IVERSON: But the disease is progressive, and there is no cure.

EXERCISE INSTRUCTOR: Roll to your right.

DAVE IVERSON: Tom Shearer has had Parkinson's for 15 years, and early on, he coped well.

TOM SHEARER: Things had been going very well. And all of sudden, out of the blue, I disintegrated. And it suddenly occurred to me that this was not a battle I was going to win.

EXERCISE INSTRUCTOR: Look back behind you, and look back behind you over here, and look back behind you--

DAVE IVERSON: Is Parkinson's a winnable battle? It's a question I've thought about ever since I got my own diagnosis, in part because it made me think about my dad.

My father was a man with an easy smile and a ready wit, and to his great good fortune, he had quite a partner at his side, my now 96-year-old mother, Adelaide.

ADELAIDE: It's such a natural picture, really.

DAVE IVERSON: [on camera] Yeah, well, I don't think he would have been posing like that. [laughter]

ADELAIDE: Well, who knows? You remember he was the Lone Ranger once.

DAVE IVERSON: [voice-over] My father was a performer at heart, and my parents married not long after he'd finished a stint in radio, working on the original Lone Ranger.

[on camera] I love this letter from his broadcasting company.

ADELAIDE: Oh, this a wonderful letter. Read it.

DAVE IVERSON: "It is with regret that we learn that Bill is considering the completion of his course, as he has a fine voice, good vocabulary and an instantaneous mind." I always loved that phrase, an "instantaneous mind."

[voice-over] My dad left broadcasting to become a teacher, but the spoken word remained central to who he was. Language was his gift, a gift that began slipping away in the fall of 1971.

ADELAIDE: I was walking with him, and I thought he was holding his hand just not in an ordinary way. It was- it looked stiff and different.

DAVE IVERSON: It was the first sign of Parkinson's, a condition that not only steals movement, it can rob you of something more.

ADELAIDE: He was mostly concerned about his voice because he did have a good voice, and that deteriorated gradually. Toward the end, he really couldn't talk.

DAVE IVERSON: [on camera] You think that was the hardest for him?

ADELAIDE: Hardest. By far the hardest thing. It was harder than not moving, actually, I think, in many ways.

DAVE IVERSON: My brother, Peter. Like siblings everywhere, we've talked about how we grew up, what we took from our parents, including how our Dad dealt with Parkinson's.

PETER: I think he conveyed to us, you know, one way or another a sense about life in general being a fragile enterprise. I think he was one of those people who- you know, immigrant's son who said, "No excuses, no whining, get to work."

DAVE IVERSON: Like my dad, Peter became a teacher. And in the summer of 1992, 20 years after my dad's diagnosis, he too felt the same first signals of the disease.

[on camera] Do you remember having a sort of sense of foreboding about that?

PETER: I think that's it. There had been too many signs, you know, too many physical manifestations, too many indications to think otherwise. It's always there. It's one of the first things you think about in the morning and one of the last things you think about at night. And it says to you, you know, Take advantage of the time you have. You work a little harder. And you realize the timetable is not the same.

DAVE IVERSON: Do you remember the conversation that you and I had when I called you up and told you that I had been diagnosed, as well?

PETER: Yeah, I do remember that.

DAVE IVERSON: Do you remember what you said to me?

PETER: Mercifully, I don't. But I'm about to reminded, I think.

DAVE IVERSON: No, I've always remembered it. You said, "We'll just have to fight this together."

PETER: I do remember.

DAVE IVERSON: [voice-over] My father, my brother and me, we share a common journey, and now I find myself wondering about the road ahead, what I might learn and what might slip away.

PHYSICIAN: Bring your hands close to your chest, but don't touch the fingers.

DAVE IVERSON: Given my family story, I couldn't help but wonder if Parkinson's was genetic.

PHYSICIAN: Look here. And look here.

DAVE IVERSON: So I enrolled in a study at Jacksonville's Mayo Clinic. Until recently, the idea that your DNA might cause Parkinson's was considered unlikely. But geneticists like the Mayo Clinic's Dr. Matthew Farrer are now taking a closer look at the role of the family tree.

MATTHEW FARRER, Ph.D., Mayo Clinic, Jacksonville: There were no genetics in Parkinson's disease 10 years ago. None. This century, in the 21st century, it's genetics. The genetics provides molecular clues, rational clues as to what's going on in the disease process.

DAVE IVERSON: In the past 10 years, Farrer and other geneticists have found mutations that cause Parkinson's in six different genes, and they're looking for more.

RESEARCHER: Tell me about your family and I can just draw them in.

DAVE IVERSON: So there's me, and I have Parkinson's. And so does one of my brothers. And my father had Parkinson's.

[voice-over] And beyond individual family ties, geneticists are now tracking Parkinson's genes in whole populations.

PHYSICIAN: It's my understanding that you come from Norway, your background is Norwegian?

DAVE IVERSON: [on camera] Yeah, my grandfather was born in Norway, in Larvik, Norway.

PHYSICIAN: Your grandfather on which side?

DAVE IVERSON: My father's.

[voice-over] In 2004, Mayo scientists helped discover the most common Parkinson's mutation in the LRRK2 gene. They've now traced it to several locations, including North Africa, near the ancient site of Carthage, and oddly enough, to my ancestral home, the coast of Norway.

MATTHEW FARRER: It spread to Norway, we think, because of Viking occupation. There were Vikings living in and around Carthage at around 1000 AD, and this particular mutation is quite common on the northern coastline of Norway.

DAVE IVERSON: My grandfather's birthplace is on the Norwegian coast, next door to Norway's first Viking settlement. So did my own family's Parkinson's saga begin a thousand years ago, when some seafaring relative came calling in Carthage?

MATTHEW FARRER: With your particular description of your disease and your family history and origin, there's quite a high chance, I would think, that you have a genetic form of the disease.

DAVE IVERSON: Quite a high chance, though still not certain. But oddly enough, that possibility might bring a bit of family luck. And here's why. This is a graphic representation of the LRRK2 gene, the gene in question, and it offers researchers a ready-made target for fixing the disease. Farrer thinks that the key is repairing what he calls the gene's faulty doorway.

[on camera] It's the hinge of the door that you want?

MATTHEW FARRER: That's broken. The hinge is broken. The door is always open.

[www.pbs.org: More on the genetic trail]

DAVE IVERSON: And the thought would be to create a drug that could close that door?

MATTHEW FARRER: Actually, fill the doorway, get in the way.

DAVE IVERSON: [voice-over] Finding a drug that would fix the mutation would be great news for potentially affected families like mine. But Parkinson's usually appears out of nowhere, with no family ties in sight. So besides genes, there must be something else that jump-starts the disease.

One theory first made news more than 20 years ago--

NEWS ANCHOR: First, a background report on Parkinson's disease by Dave Iverson of public station WHAA, Madison, Wisconsin.

DAVE IVERSON: And in one of life's little ironies, it was a story that I had covered, too.

This is what's known about Parkinson's disease. It's progressive and it's incurable.

In the mid-1980s, I'd reported on the work of a young Stanford neurologist named Bill Langston, who'd come across something startling that seemed to cause Parkinson's. Now, more than 20 years later, I've headed back to Bill Langston's Parkinson's Institute. Since the 1980s, Langston and his team have investigated whether environmental toxins might trigger the disease, a quest that began with a most unusual patient.

WILLIAM LANGSTON, M.D., Parkinson's Institute: It really started with my getting called to see a patient who had developed Parkinson's literally over two or three days. And he was young. That's not typical. It came on quickly. That's not typical. So he was a true medical mystery.

PHYSICIAN: Can you raise this hand up at all? Can you raise that hand up?

Dr. WILLIAM LANGSTON: He was literally frozen like a statue.

PHYSICIAN: I can see you trying.

Dr. WILLIAM LANGSTON: So I knew instantly we had a neurological condition on our hands. But what? We had no idea.

DAVE IVERSON: What Langston and his team were about to discover would turn the Parkinson's world upside down.

Dr. WILLIAM LANGSTON: In taking a history, we asked him if he was on any medications, and to our shock, he wrote the word "heroin." Not a traditional medication, but that was our first clue. We were eventually able to figure out that there was a tainted heroin on the streets in northern California and that this heroin was probably the most selective brain toxin ever discovered.

After these addicts shot up, it went straight into the brain like a Nike missile and literally killed the same cells in the brain that died in Parkinson's, and we had literally instant Parkinson's disease.

DAVE IVERSON: But did this condition really equate to normal Parkinson's? One test would be to see whether standard Parkinson's drugs would help.

PHYSICIAN: Can you hop up and down?

Dr. WILLIAM LANGSTON: And the results were truly dramatic. It literally brought these patients back to life.

PHYSICIAN: Your left foot, your right foot--

DAVE IVERSON: But just a half hour later, the Parkinson's medication begins to wear off. And soon, the patient is back to his frozen state.

PHYSICIAN: How do you feel now? You can't move?

DAVE IVERSON: Langston now knew a street drug could cause a Parkinson's-like condition, but what the scientists discovered next radically altered the nature of Parkinson's research. It turned out that the synthetic heroin, MPTP, had a chemical make-up strikingly similar to a widely used herbicide, paraquat.

Dr. WILLIAM LANGSTON: That was an "Aha" moment because if here a compound could cause all the motor symptoms of Parkinson's, was also very, very chemically similar to an herbicide that's widely used, it really raised the question how many of those things are out there.

We now are hunting, specifically looking for one or more chemicals in the environment, that might play a role in Parkinson's disease.

DAVE IVERSON: The findings galvanized the scientific community. Researchers began looking into whether Parkinson's was caused by a variety of environmental triggers, and history seemed to support that approach. Scientists knew that Parkinson's hadn't even appeared in the medical literature until 1817, the beginning of the industrial revolution, when toxins were first poured into the environment. They now wondered if Parkinson's could be, at least in part, a modern disease, triggered by toxins like MPTP.

Dr. WILLIAM LANGSTON: I think it's a very exciting time for research into this disease. And for patients with Parkinson's disease and their families, that's good news. Thank you very much.

We had real hope that this would solve the disease, and I thought, three to four years, we would have the answer. In fact, in three to four years, we did have an answer and that was that probably MPTP itself was not "the" cause of Parkinson's.

DAVE IVERSON: Not "the" cause, but a key clue. Indeed, recent studies have built on Langston's initial breakthrough, showing that pesticide exposure can increase disease risk by as much as 70 percent. And many scientists now think genes and the environment might actually work hand in hand to cause most Parkinson's, with certain genes triggering the disease only when a toxic exposure takes place.

Dr. WILLIAM LANGSTON: There's an old saying that genetics loads the gun and the environment pulls the trigger and that may be the case in Parkinson's. We still don't have a smoking gun, that's for sure, but that's what we're looking for.

[www.pbs.org: Read Langston's interview]

DAVE IVERSON: And so the time-consuming hunt for what causes Parkinson's continues. But time, of course, is what people with Parkinson's can least afford. For them, the quest that matters most is the search for a cure.

PAULA CHIASSON, Dalhousie Univ., Nova Scotia: When I first met Peter, he was a man who was truly suffering. You know, he was a thoughtful, intelligent man, but he had some real periods of disability. And he was really desperate and hopeful that we could do something to kind of give him his life back.

PETER SAUER: I actually didn't know how bad I was until I saw myself. And I felt like somebody should take me out and shoot me. I didn't know that I had gone downhill that much.

DAVE IVERSON: In 1999, Canadian Peter Sauer went to see a team of specialists in Halifax, Nova Scotia. His symptoms could no longer be controlled by Parkinson's drugs. The Halifax team, led by Dr. Ivar Mendez and Harvard neuroscientist Ole Isacson, was trying to refine a controversial procedure they hoped would lead to a cure, a fetal brain cell transplant.

OLE ISACSON, M.D., Harvard University: What we're learning is how to reconstruct the brain. Cells can actually be put back into the brain, they can grow new connections and release this transmitter, this chemical, dopamine, in a natural and appropriate way.

DAVE IVERSON: The idea was to restart dopamine production by taking fetal neural cells derived from aborted tissue and transplanting them into a patient's brain.

IVAR MENDEZ, M.D., Dalhousie Univ., Nova Scotia: Now we talk about the concept of brain repair. Brain repair, you know, when I was in medical school, which is really not that long ago, was not even something that was thought about. So we have advanced tremendously to understand that we can potentially repair the brain.

DAVE IVERSON: But would brain repair work for Peter Sauer? Images taken of a brain from a previous transplant recipient were promising.

Dr. IVAR MENDEZ: From this bunch of cells, you can see these little wiggly brown fibers that are growing and restoring that area of the brain that is affected by Parkinson's disease.

DAVE IVERSON: By way of comparison, here's the same section of the brain from a Parkinson's patient who did not have a transplant. Here there's no evidence of brain cell activity at all.

[on camera] There's nothing going on there.

Dr. IVAR MENDEZ: Yeah, there's nothing going on.

DAVE IVERSON: [voice-over] The microscopic evidence is compelling, but the evidence in person is stunning. Here's Peter Sauer at the age of 65, as seen without medication prior to his transplant. And here's Peter Sauer age 72, without medication today.

Dr. IVAR MENDEZ: You look really fantastic, Peter.

PETER SAUER: I don't know what to say. I feel fantastic. [laughter] I turned out to be the wunderkind. I don't know why that is.

PAULA CHIASSON: Today I see a man who is full of life and energy. I'd actually have a hard time keeping up with Peter. When I see things like that and I remember the way patients were before the surgery, it's like witnessing a miracle because you see they really do have their lives back. It's quite something to witness.

DAVE IVERSON: But for people with Parkinson's, the hope engendered by stories like Peter Sauer's proved short-lived. A year after Peter's procedure, a series of fetal transplants at the University of Colorado, utilizing a different surgical technique than the Halifax team, yielded deeply disappointing results. While some recipients showed modest improvement, others wound up far worse, unable to even control their own bodies.

Dr. OLE ISACSON: Even though some patients recovered, some patients recovered too much. In other words, they started to show excessive movements, rather than just enough. So instead of being helped, they were actually made worse.

DAVE IVERSON: It was a demoralizing setback, and despite the Halifax success, served to largely freeze the field of fetal transplants in its place.

Dr. WILLIAM LANGSTON: There's an old saying in science that research is the process of going up alleys to see if they're blind. And more often than not, they are. But that's what we do.

DAVE IVERSON: Meanwhile, the clock ticks. This year, some 50,000 people in the United States will wake up and sense something's wrong. They're more likely to be men than women, more likely to be people my age. But sometimes that unwelcome wake-up call arrives when you're young, when your career is just taking off.

[www.pbs.org: More on the demographics]

["Doc Hollywood"]

MICHAEL J. FOX: Since you're obviously not a patient and I'm not getting anywhere, can you tell me where I can find a guy named Lou who drives an ambulance? I'll get out of your life.

JULIE WARNER: I'm Lou.

MICHAEL J. FOX: I was doing a film in Florida and was partying pretty good and was used to not waking up not in great shape, but I woke up one morning and my pinky was twitching. And it was just persistent, and I just- I realized there just was nothing I could do to stop it. And I thought, "Is this, like, DTs? Who gets DTs in their pinky?"

You know, a lot of injury or a lot of catastrophic illness, it's like stepping off a curb and getting hit by a bus. But with Parkinson's, it's like actually being stuck in the middle of the road while a bus is coming. And you can hear it, you have no idea how big it is, you have no idea how fast it's going, and you have no idea whether it's going to hit you all the way or just going to graze you and screw you up. It's a lot to think about.

It's not anything that I was ready to introduce to the neighbors until I really understood it.

DAVE IVERSON: [on camera] Do you remember a time when you were at peace with the bus coming?

MICHAEL J. FOX: There was a time I was talking to my therapist, and you know, I said, "Everything is great in my life"- wonderful, my kids and my wife. My work was going well. But I said to her, "You know, I still- I feel like I'm still waiting for the other shoe to drop. And she said, "You have Parkinson's. The other shoe already dropped. And it was just this- I just went, "Wow. You're right. I mean, what are they going to do to me?"

DAVE IVERSON: [voice-over] Michael J. Fox kept his diagnosis secret for seven years. But at the age of 37, he decided it was time to go public and bring new attention to the disease.

MICHAEL J. FOX: When you're faced with something real, it demands something of you that you wouldn't have chosen for yourself. This is a real opportunity for me to help people.

DAVE IVERSON: The same month that Michael J. Fox went public, November 1998, Parkinson's was back in the headlines for a different reason.

NEWSCASTER: For the first time, researchers have generated cells that are the basis of human life, and this could radically change the way medicine fights disease.

DAVE IVERSON: A startling scientific development, embryonic stem cells, cells that are derived from embryos rather than fetal tissue, opened a new door of possibility. Suddenly, there was the promise of creating cells that could replace what goes wrong in any number of diseases, and Parkinson's was Exhibit A.

Dr. OLE ISACSON: Embryonic stem cells can generate any cell type in the body, including the dopamine cell that we were looking for. When we discovered that stem cells could actually develop into this very cell that we know is therapeutic for the patient, it was very exciting.

DAVE IVERSON: Scientists hoped that the new cells would provide more consistent patient treatment than some of the earlier fetal tissue experiments. But there was a catch. Embryonic stem cells are created from frozen human embryos left over from fertility clinics, and creating the new cells destroys the embryos, prompting intense controversy about the possibilities contained in a petri dish.

One key question was how federal funding for the controversial new research might impact diseases like Parkinson's.

[Senate Appropriations Subcommittee, Sept. 28, 1999]

Sen. ARLEN SPECTER (R), Pennsylvania: Will the elimination of the restriction on stem cells be a significant factor in expediting solving Parkinson's?

Dr. GERALD FISCHBACH, Neuroscientist, NIH: Yes, it certainly will. It will certainly lead to a more rapid solution to this problem.

DAVE IVERSON: In the fall of 1999, Senator Arlen Specter convened a hearing on Parkinson's.

Dr. WILLIAM LANGSTON: With a focused effort- the pieces are in front of us, the science is there- I think we can make major progress towards this disease.

DAVE IVERSON: A series of experts testified about the scientific promise of stem cells. Hope was running high that a cure was now within reach.

Dr. GERALD FISCHBACH: We are close to solving- and I mean the word "solving" Parkinson's disease. With a little bit of skill and luck, 5 to 10 years is not unrealistic.

DAVE IVERSON: That timeline had a particular impact on one person in attendance.

MICHAEL J. FOX: When I heard Parkinson's could be cured within 5 to 10 years with the proper funding, at once, I knew two things. I knew that it wasn't going to happen, but I knew that if it could happen, that these people were saying that it could happen. That's all I needed to know, was that- was that- that the science was ahead of the money.

DAVE IVERSON: The hearing inspired Fox to start his own foundation, which soon became the leading independent funder of Parkinson's research. But Fox also knew that federal support for stem cell science remained crucial.

One year later, just weeks before the presidential election of 2000, Arlen Specter convened another hearing.

[September 14, 2000]

Sen. ARLEN SPECTER: We call Ms. Jennifer Estes, Ms. Mary Tyler Moore and Mr. Michael J. Fox.

DAVE IVERSON: This time, he brought in some high-profile advocates for a number of diseases to kick off the debate.

Sen. ARLEN SPECTER: We do thank you for joining us.

MICHAEL J. FOX: Thank you Mr. Chairman. I'm one of a million involuntary experts on Parkinson's disease in the United States, battling its destructive nature as we wait for a cure. Please help, us to not wait any longer than we have to. We urge you to not let politics interfere and needlessly delay this critical research.

DAVE IVERSON: The hearing, and the larger debate, hinged on one question, how we choose to view research that depends on leftover frozen embryos from fertility clinics.

Sen. TOM HARKIN (D), Iowa: Once you have in vitro fertilization, you've got all these frozen embryos, 100,000, I guess, that are frozen. They're just not going to be kept forever and ever and ever and ever. They're going to be discarded. So if they're going to be discarded, is it more ethical and moral, then, to use these in a method that might reduce human suffering than it is to discard them?

Rev. RUSSELL SALTZMAN, Kansas City, Missouri: If these embryos are going to be discarded anyway, I know the argument goes, then why not go ahead and use them. We have prisoners on death row who are going to be executed anyway. Why not get some use out of them before they're dead? All of this cheapens, I think, human life and our respect for it.

CHARLES KRAUTHAMMER, Syndicated Columnist: It's infinitely easier to lose sight of humanity if it's a little embryonic ball of tissue. And to me, it's not a full human being, but it is more than a piece of appendix.

DAVE IVERSON: Syndicated columnist Charles Krauthammer suffers from a spinal cord injury that might someday benefit from a stem cell breakthrough. He supports most forms of the research, but he, too, had moral concerns about that pinpoint of potential.

CHARLES KRAUTHAMMER: The fact that it has the potential to become human, and if unmolested and implanted, it will become human, then it deserves a certain kind of respect.

MICHAEL KINSLEY, Time Magazine Columnist: Embryonic stem cell research uses embryos that are fewer than 200 cells. You can't even barely see them without a microscope.

DAVE IVERSON: Time magazine columnist Michael Kinsley has Parkinson's. For him, frozen embryos that would otherwise be discarded represent potential of a different sort.

MICHAEL KINSLEY: There is hope, you know, real hope, and much of it comes from stem cells.

DAVE IVERSON: The battle lines were drawn, but a final decision would have to wait. There was an election to be held and the choice would now be up to the next president of the United States.

Pres. GEORGE W. BUSH: [August 9, 2001] Good evening. The issue of research involving stem cells derived from human embryos is increasingly the subject of national debate. As the genius of science extends the horizons of what we can do, we increasingly confront complex questions about what we should do.

DAVE IVERSON: In August 2001, President Bush announced his decision. Federal funding would be limited to existing stem cell lines. No new embryos could be used, a policy that created major obstacles in the search for new treatments.

MICHAEL KINSLEY: There are many therapies very common in chronic diseases of all sorts where there's an age cut-off, and if you're over a certain age, you can't get it. It could well be that when the big breakthrough comes, I will be four or five years past that age. And if that happens, I'm going to be really annoyed, at George W. Bush in particular.

DAVE IVERSON: The stem cell controversy would continue to simmer throughout the Bush years. But by the summer of 2006, a bipartisan majority in Congress emerged, passing legislation to free up more funding.

Sen. DIANNE FEINSTEIN (D), California: We're going to see whether the first veto that the president of the United States makes in his entire political career will be a veto which will dash the hopes of millions of Americans.

DAVE IVERSON: But stem cell opponents, including various conservative Christian groups, urged President Bush to hold the line. And one day after the Senate voted to ease funding restrictions, the president responded.

Pres. GEORGE W. BUSH: [July 19, 2006] This bill would support the taking of innocent human life in the hope of finding medical benefits for others. It crosses a moral boundary that our decent society needs to respect. So I vetoed it.

MICHAEL J. FOX: You know, when you're talking about the potential to heal and cure so many and it not going forward because of its value as a wedge issue, it pissed me off. And I wanted to do something. I just put the word out to anybody on either side of the aisle if they were pro-embryonic stem cell research and they wanted my help, or welcomed my help - if they wanted me to stay away, I'd do that, too - but I was available.

DAVE IVERSON: One key contest in 2006 was the Missouri Senate race between Republican Jim Talent and Democratic challenger Claire McCaskill.

MICHAEL J. FOX: [McCaskill campaign commercial] As you might know, I care deeply about stem cell research. In Missouri, you can elect Claire McCaskill, who shares my hope for cures. What you do in Missouri matters to millions of Americans, Americans like me.

DAVE IVERSON: But Fox's activism didn't please everyone.

RUSH LIMBAUGH, Radio Talk Show Host: He's moving all around and shaking, and it's purely an act!

MICHAEL J. FOX: It- I- it just made me smile. I was just, like, “No! Really? He really said that?" And then I realized that we're in the last two weeks of the campaign and people were talking about stem cells. And as long as that happens, I'm happy. You can call me whatever you want.

[www.pbs.org: More of Fox's interview]

NEWSCASTER: Missouri went to Democrat Claire McCaskill.

CLAIRE McCASKILL, Senator-Elect: The nation was watching, and we showed 'em! Thank you so much!

DAVE IVERSON: Claire McCaskill won that pivotal Missouri Senate race, and the Democrats claimed control of Congress. But there still weren't enough votes to overturn a presidential veto, and the funding restrictions remained in place for the remainder of the Bush presidency.

Dr. WILLIAM LANGSTON, M.D., Parkinson's Institute: It has obviously slowed research in this country. It's been, I think, a miserable time for everybody, very sad epoch in our history.

CHARLES KRAUTHAMMER: I think the president will always be remembered for having raised the moral consciousness of the nation about the moral issues, and that's what his main contribution will be.

MICHAEL KINSLEY: Even if the issue of stem cells disappeared tomorrow, I would judge George W. Bush quite harshly. Six years have gone by, and you know, those are six important years to people like me, for example.

DAVE IVERSON: The Obama administration may soon reverse the Bush stem cell policy, and scientific breakthroughs may open up whole new approaches less reliant on embryonic stem cells. Still, Parkinson's remains a race between the disease and the clock.

Back home in the Bay Area, I met up again with Tom Shearer, who I'd first gotten to know at the Parkinson's exercise class. It was Tom who first said to me that this wasn't a battle he thought he could win..

What worries Tom and his wife, Madeleine, now isn't so much the struggle to keep moving, but the battle everyone dreads, the one that involves your mind.

TOM SHEARER: One of the real major problems that I think almost anybody with Parkinson's has, which is the memory aspect. I don't know where that's going to lead.

MADELEINE: There was a long period when Tom would go out and get lost, and neighbors would call us and say, "Come and get him. He's at the corner of such and such."

TOM SHEARER: I did get lost in downtown Oakland. If you've lived in this area, you know, you really shouldn't get lost.

DAVE IVERSON: Parkinson's requires, of all things, a kind of gracefulness, an ability to shift and adapt, to change medications for what feels like the millionth time and still smile.

MADELINE: Aracept, which makes you smarter, so every now and then, I steal one.

Well, it's much better now than it was when Tom was getting confused. He's sharp. He laughs. He makes jokes.

DAVE IVERSON: For the Shearers, fighting the battle is about making adjustments.

MADELEINE: I think this is just if you're filing electronically.

DAVE IVERSON: Tom used to be a tax attorney, but Madeleine now files their returns.

Watching Tom and Madeleine Shearer, I think back to my parents, the adjustments they made, little things, like the difference a shoehorn can make, and that even as speech becomes more difficult, it still only takes a few words to sum up how best to face the future.

TOM SHEARER: Shoes on again.

MADELEINE: Yeah.

DAVE IVERSON: Shoes on again. The day after I got my diagnosis, I began an exercise regimen, mostly just because I wanted to feel like I was still in charge of my own body. And the more I learned about exercise, the more hopeful I became. Research at one location was particularly intriguing, the University of Pittsburgh and the lab of Dr. Michael Zigmond.

MICHAEL ZIGMOND, Ph.D., University of Pittsburgh: Parkinsonian researchers are sort of late in the game of being interested in exercise. People interested in Alzheimer's disease have been studying exercise for quite a while. People that worry about depression have been studying exercise for a long time. I think it's generally understood that if you're feeling blue, going for a run is a good way to deal with it. So all of those things - cognitive deficits, depression and motor deficits - all occur in Parkinson's disease.

DAVE IVERSON: Zigmond suspects the connection between exercise and Parkinson's goes way back in time.

MICHAEL ZIGMOND: It was probably not so many generations ago that our forbears were much more active than you and I are. The species that we evolved from probably spent a great deal of time running away, so we wouldn't be prey, or running after, so we would get prey. We don't do that anymore.

DAVE IVERSON: And could the fact that we exercise less while living in a more toxic environment be another indicator that modern life is making matters worse?

MICHAEL ZIGMOND: It's ironic that they go hand in hand- more toxins, less exercise.

DAVE IVERSON: Or to put it the other way around, would more exercise mean less Parkinson's? The answer to that question may come from a surprising source.

JUDY CAMERON, Ph.D., University of Pittsburgh: We're probably the only lab in the world that runs monkeys on treadmills. So it is not an everyday occurrence.

DAVE IVERSON: To test the impact of exercise on Parkinson's, the University of Pittsburgh's Dr. Judy Cameron has divided monkeys into two groups, the runners and the watchers. The running monkeys train for three months. The watchers- well, they just watch. And then both groups are injected with the toxin MPTP, the same toxic substance that caused instant Parkinson's in the frozen addicts.

JUDY CAMERON: What we're seeing is the monkeys that have run on the treadmill have very little effect of the MPTP. They're still able to use the side in which they received the injection and they can use it very normally. The monkeys that are running look very different from the sedentary controls. The sedentary controls aren't really using their arm. They're letting their arm hang down. It makes us think that exercise somehow changes how the brain is functioning and protects it against damage.

DAVE IVERSON: To see exactly what's going on, the animals are then given a brain scan. The results prove to be dramatic.

JUDY CAMERON: It's a pretty massive lesion.

DAVE IVERSON: The MPTP injection has decimated dopamine production in the monkeys who watched but didn't run.

RESEARCHER: But in contrast, the running animal--

JUDY CAMERON: The lesion is much less.

RESEARCHER: Yeah. In fact, in some of these slices, you'd be hard pressed to know that there is a lesion at all.

JUDY CAMERON: Right, so-

DAVE IVERSON: In fact, while the MPTP knocked out dopamine production on one side of the brain in the sedentary monkeys, the running monkeys were only minimally affected. Their dopamine production remained virtually normal.

JUDY CAMERON: So what we're finding is that when we exercise the monkeys on the treadmill for the amount of exercise that clinicians would recommend that middle-aged people undertake, their brain is less likely to be damaged when there's an insult.

DAVE IVERSON: And that's the key question. Is what's good for the monkey good for you?

TOM MANNING: What I'm really excited about is to see how I do on the stress test at the end of this. I'm going to blow them out of the water. Just mark it down in your little pad, Tom's going to blow them out of the water.

DAVE IVERSON: Laurel Maryland resident Tom Manning is already a believer. He's had Parkinson's for seven years, and at the age of 75, he's more than willing to work up a sweat both on the treadmill and on the job.

TOM MANNING: The reason I keep working- I don't need the money. The last thing in this world I need is any money. I keep working because it keeps me breathing. It keeps me exercising. I've got to be doing something productive.

The secret to Parkinson, I found out- and now, I can't justify it scientifically, but work helps Parkinson, plain and simple.

DAVE IVERSON: Actually, Tom Manning may soon be able to prove it scientifically. He's part of a major new study at the Baltimore VA and the University of Maryland. And oddly enough, Dr. Lisa Shulman says it's one of the first times the impact of exercise on Parkinson's has been evaluated.

LISA SHULMAN, M.D., Univ. of Maryland School of Medicine: Maybe there's been a cultural perspective that's embraced pharmaceuticals and surgical approaches and has considered lifestyle changes to be very soft and not as worthy of study,

Any pain in your legs or your arms or anything?

PATIENT: No.

Dr. LISA SHULMAN: All right. Great job.

But It's not at all hard for me to imagine that the results of a properly designed exercise program are going to be more effective than many of the medications we have now.

DAVE IVERSON: If time on the treadmill is as important as the pills you take, it may be because exercise increases something called growth factors, proteins that scientists think are essential to support the brain.

CLIVE SVENDSEN, Ph.D., Univ. of Wisconsin, Madison: When your dopamine neurons grow very early on in development, they require growth factors for nurturing. If that neuron becomes damaged through Parkinson's disease, it seems to become dependent again on that growth factor.

DAVE IVERSON: University of Wisconsin scientist Clive Svendsen is intrigued by how growth factors might boost brain performance.

CLIVE SVENDSEN: It's rather like the fertilizer for your lawn. If the lawn looks bad, you put some fertilizer on it and it starts growing beautifully again. And growth factors are fertilizer for the brain, essentially.

DAVE IVERSON: Svendsen wants to surgically deliver growth factors to the brains of Parkinson's patients using stem cells because they're ideally suited for a stealth-like role.

CLIVE SVENDSEN: The idea is to design stem cells that make this drug, put the stem cells in the brain, and then they'll deliver it rather like a Trojan horse. The brain accepts the stem cell because it's neural and it's going to integrate and migrate and get into the brain tissue.

DAVE IVERSON: Svendsen's idea is still in development, but clinical trials using another surgical technique have so far proved disappointing, which points to why the treadmill retains a certain advantage. With exercise, the growth factor boost happens in-house, no surgery required.

MICHAEL ZIGMOND, Ph.D., University of Pittsburgh: So one of the reasons that we are very interested in the possibility that exercise can be protective is that the actual release of dopamine is still in the hands of the nerves. The nerves release it when they want to release it, to the place that they want to release it into, at the right concentration.

DAVE IVERSON: [on camera] So in a way, it's the most natural or holistic sort of solution?

MICHAEL ZIGMOND: Yeah. I think so.

LISA SHULMAN, M.D., Univ. of Maryland School of Medicine: As a physician, we really need something that will help somebody realize "I can get back into life again." Maybe exercise is that.

DAVE IVERSON: [voice-over] For Tom Manning, exercise is not only about getting back into life, it's about staying in charge of it.

TOM MANNING: It gives me a goal. It gives me something that I can reach out for and to achieve. I'm the captain. I'm in charge of this ship. And if it runs up on the reefs, I'm going to get it back off the reefs. I'm going to keep on sailing.

DAVE IVERSON: And so I keep running. Twenty-five years after Bill Langston showed a potential link to herbicides, we're still searching for definitive environmental triggers. And therapies involving genetics, growth factors and stem cells have big challenges to overcome, which means that for now, the central question remains how you live with Parkinson's

DAVID LEVINTHAL, Mark Morris Dance Group: -and just massaging around your forehead, and into your temples and into your cheeks.

DAVE IVERSON: For Tom Shearer and some of his exercise class friends, that includes taking up dance.

DAVID LEVINTHAL: I will say my name with a gesture, and then everyone will repeat once, and then we'll go around to the next person.

DAVE IVERSON: The class is led by David Levinthal and John Heginbotham of the Mark Morris Dance Group.

JOHN HEGINBOTHAM, Mark Morris Dance Group: John.

CLASS: John!

CLASS MEMBER: Robert.

CLASS: Robert!

JOHN HEGINBOTHAM: It's only ever a wonderful experience to teach people with Parkinson's to dance. I teach a variety of classes, often things for professional-level students, and I can go to this high-level class and there really is not any dancing happening. And when I come to teach the Parkinson's class, I'm seeing dancing happen.

DAVID LEVINTHAL: They're there to express themselves. They're there to cross a boundary. That sort of unbridled enthusiasm and passion and free expression is really what I see in their faces and their bodies. This is one of those very special places where that happens. It's magical.

MICHAEL J. FOX: I mean, life's the best deal we've got. It's the best thing we've got going. And I'm really blessed. I'm really lucky.

DAVE IVERSON: In his memoir, Lucky Man, Michael J. Fox wrote that he wouldn't go back to the life he had before Parkinson's.

MICHAEL J. FOX: No, absolutely not. I mean, this is my experience. It's asked so much of me that I never would have asked of myself. So no, I wouldn't change that. You know, I've written about kind of walking by a mirror and seeing myself looking pinched and shaking and hunched, and then seeing the corner of my mouth go up in a smile. And I just think, "What are you smiling about?" But the fact that I can look at the world the way that I do, whatever that is that made that happen, I wouldn't want to risk changing it by changing anything that's happened since.

DAVE IVERSON: Parkinson's does ask a lot. And so in the end, it's how we answer that matters.

ADELAIDE: After all, we were very, very fortunate in our life. And we lived a long time. Look, it goes without saying, I'm still here. But Bill had a good life. We traveled. We just did it. I can't imagine to this day having had a better life.

PETER: The best thing to do and maybe the only thing to do is to keep looking forward and to value and honor and believe in those friends and family members, loved ones who continue to believe in you.

DAVE IVERSON: We usually think of time as the enemy, but I've come to think that time is also an ally. Yes, the disease is progressive, but so too is science. And as we await those discoveries, we have at our fingertips the enduring power of the human spirit to be passed on from one to the next.

I don't know what lies ahead, but I already know there will be remarkable people along the way, just as there have always been.

ADELAIDE: When I see you go out for hikes and walks, I just think how great that is and how hopeful I am.

DAVE IVERSON: [on camera] Me, too.

ADELAIDE: And I think that there are things on the road that will make it continue. I refuse to think any other way.

DAVE IVERSON: Me, too.

[In January 2009, Peter Sauer passed away from causes unrelated to Parkinson's.]

My Father, My Brother and Me

PRODUCED AND DIRECTED BY
Dave Iverson and Michael Schwarz

CORRESPONDENT
Dave Iverson

SENIOR PRODUCER
Ken Dornstein

EDITOR
Gail Huddleson

CAMERA
Vicente Franco

ADDITIONAL CAMERA
John Chater
Eddie Marritz
Gary Mercer
Phil Geyelin
Andy Heikkila

SOUND
Ray Day

ADDITIONAL SOUND
Adriano Bravo
Tom Craca
Brian Haughin
John Osborne
Mark Mandler
Tom Naunas
Len Schmitz
David Strayer
Andrew Watt

ORIGINAL MUSIC
Christopher Rife

ONLINE EDITOR
Jim Ferguson

SOUND MIX
Jim Sullivan

EXECUTIVE IN CHARGE OF PRODUCTION
Kiran Kapany

POST PRODUCTION SUPERVISOR
Ryan Shake

ARCHIVAL RESEARCH
Betsy Bayha

ASSISTANT EDITOR/PRODUCTION ASSISTANT
Jeremy Belzer-Adams

PRODUCTION ASSISTANTS
Courtney Norris
Sarah Fitzgerald
Karen Hansen

PRODUCTION ACCOUNTANT
Rebecca Haseleu

VISUAL EFFECTS
Edgeworx

NARRATION RECORDING
Berke Sound

COMMUNITY ENGAGEMENT
Active Voice

ARCHIVAL MATERIALS
Terry Salomonson, Audio Classics Archive
Corbis
CNN
Getty Images
National Geographic Digital Motion
NBC News Archives
The CONUS Archive
The Gleaners, 1857 (oil on canvas) by Jean-Francois Millet (1814-75) Musee d'Orsay, Paris, France / The Bridgeman Art Library
The University of Colorado
The University of Wisconsin
The Wood Sawyers, 1848 (oil on canvas) by Jean-Francois Millet (1814-75) Victoria & Albert Museum, London, UK / The Bridgeman Art Library
The WPA Film Library
WGBH Media Archives

SPECIAL THANKS
John Argue's Parkinson's exercise class
Holly Barkhymer
Dr. Chad Christine
Katie Hood
Rick LeCompte
Northern California Public Broadcasting
Michael Schwarzschild
Andrew Singleton
Wisconsin Public Television
Kenji Yamamoto

EXECUTIVE PRODUCER FOR ITVS
Sally Jo Fifer

FOR FRONTLINE

DIRECTOR OF BROADCAST
Tim Mangini

POST PRODUCTION
DIRECTOR
Chris Fournelle

ON AIR PROMOTION
PRODUCER
Missy Frederick

AVID EDITORS
Jim Ferguson
John MacGibbon
Michael H. Amundson

ASSISTANT EDITORS
Mark Dugas
Tyrra Turner

POST PRODUCTION
ASSISTANT
Megan McGough

SERIES MUSIC
Mason Daring
Martin Brody

SENIOR PUBLICIST
Diane Buxton

PUBLICIST
Alissa Rooney

OUTREACH MANAGER
Sandy St. Louis

INTERACTIVE MARKETER
Jessica Smith

PROMOTION DESIGNER
Peter Lyons

PROMOTION ASSISTANT
Beth Lowell

SECRETARY
Christopher Kelleher

PRODUCTION SECRETARY
Carla Borras

COMPLIANCE MANAGER
Lisa Palone

LEGAL
Eric Brass
Jay Fialkov
Janice Flood
Scott Kardel

CONTRACTS MANAGER
Lisa Sullivan

UNIT MANAGER
Mary Sullivan

BUSINESS MANAGER
Tobee Phipps

WEBSITE DESIGNER
Maya Carmel

WEBSITE ASSOCIATE DEVELOPER
Bill Rockwood

WEBSITE RESEARCH ASSISTANTS
Gretchen Gavett
David Kieley

WEBSITE PRODUCERS
Richard Parr
Kirsti Potter

WEBSITE COORDINATING
PRODUCER
Sarah Moughty

DIRECTOR OF NEW MEDIA
AND TECHNOLOGY
Sam Bailey

COORDINATING PRODUCER
Robin Parmelee

STORY EDITOR
Catherine Wright

SENIOR PRODUCER
SPECIAL PROJECTS
Sharon Tiller

SENIOR EDITOR
Ken Dornstein

EDITORIAL DIRECTOR
Marrie Campbell

EXECUTIVE PRODUCER
SPECIAL PROJECTS
Michael Sullivan

SERIES MANAGER
Jim Bracciale

SENIOR PRODUCER
Raney Aronson-Rath

EXECUTIVE EDITOR
Louis Wiley Jr.

EXECUTIVE PRODUCER
David Fanning

A Kikim Media Production for WGBH/FRONTLINE and
the Independent Television Service (ITVS).

© 2009
WGBH EDUCATIONAL FOUNDATION AND KIKIM MEDIA
ALL RIGHTS RESERVED

FRONTLINE is a production of WGBH Boston, which is solely responsible for its content.

ANNOUNCER: This report continues on our Web site. Join the chat with correspondent Dave Iverson and Parkinson's experts, watch more of Iverson's interview with Michael J. Fox, learn about cutting-edge Parkinson's treatments and why solving the puzzles of this condition could unlock cures for other disorders, watch the program again on line and join the discussion at PBS.org.

Next time on FRONTLINE: On September 16th, 2008, all around the world, money stopped.

- I thought we may be presiding over the second Great Depression.

ANNOUNCER: How did it happen? And what happens next?

- It's the economic equivalent of 9/11.

ANNOUNCER: Inside the Meltdown, the first in a series of FRONTLINE investigations.

FRONTLINE's My Father, My Brother, and Me is available on DVD. To order on line, visit Shoppbs.org, or call 1-800-PLAY-PBS. [$24.99 & s/h]

FRONTLINE is made possible by contributions to your PBS station from viewers like you. Thank you.

With additional funding from the Park Foundation. Major funding for FRONTLINE and for this program is provided by the John D. and Catherine T. MacArthur Foundation, committed to building a more just, verdant and peaceful world. With additional support for this program from the Corporation for Public Broadcasting.

posted january 29, 2009

my father, my brother, and me home page · watch online · dvd/transcript · credits · site map
FRONTLINE series home · privacy policy · journalistic guidelines

FRONTLINE is a registered trademark of WGBH Educational Foundation.
Web Site Copyright ©1995-2014 WGBH Educational Foundation